Despite the negative clinical reports available (45, 70), large-sample prospective studies remain warranted to confirm the value of PSMA RLT in HCC treatment, the potential synergistic effects of combining other therapeutic modalities, and the development of individualized treatment regimens based on the patient’s genotype, staging, and other information. This evidence concerns the gene FOLH1 and hepatocellular carcinoma.